This program will include a discussion of investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form These data should be considered preliminary until published in a ID: 625921
Download Presentation The PPT/PDF document "Biochemically Recurrent Prostate Cancer:..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Biochemically Recurrent Prostate Cancer: Optimizing Detection and ManagementSlide2
This program will include a discussion of investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a
peer-reviewed journal.Slide3
Prostate CancerIncidence and Significance of BCRSlide4
Defining BCR After RPSlide5
Defining BCR After RTSlide6
Clinical Implications of a Rising PSASlide7
Mortality After BCR Following RP Retrospective Cohort StudySlide8
Current Management of BCR Prostate CancerSlide9
Diagnostic Evaluation of Patients With BCRSlide10
NaF-PET/CT An Alternative to Conventional ScanningSlide11
PET in BCR Prostate CancerSlide12
PET Radiopharmaceuticals Approved or Under Evaluation in Prostate CancerSlide13
Recommendations for PET/CT in Men With BCRSlide14
Choline: OverviewSlide15
Use of 11C-Choline-PET/CT in Patients With BCRSlide16
Example of 11C-Choline-PET/CT in a Patient With BCRSlide17
11C-Choline-PET/CT Sensitivity by PSA Level Slide18
18F-Fluciclovine (FACBC): OverviewSlide19
18F-Fluciclovine-PET/CT in BCR Prostate Cancer
BED-001 StudySlide20
Prospective Study of 18
F-Fluciclovine-PET/CT vs
11C-Choline-PET/CT in BCR Prostate CancerSlide21
Example of 18F-Fluciclovine-PET/CTSlide22
18F-Fluciclovine-PET/CT Scan Showing Metastatic Prostate Cancer 2 Months LaterSlide23
PSMA: An Investigational PET Imaging TargetSlide24
Example of 18F-DCFPyL PET/CT Imaging
in a Patient With BCR Prostate CancerSlide25
Example of 68Ga PSMA PET/CT ImagingSlide26
Targeting Oligometastatic Prostate CancerSlide27Slide28
ConclusionsSlide29
AbbreviationsSlide30
Abbreviations (cont)